Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily that is mainly expressed in enterohepatic tissues, has been discovered as a crucial regulator for balancing liver inflammatory processes and metabolism [5,6,7] and thus has become a pharmacological target for liver disorders. This evidence concerns the gene NR1H4 and liver disorder.